Categories: News

StageZero Announces 2020 Year End Analyst and Investor Call

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

TORONTO, ON / ACCESSWIRE / March 31, 2021 / StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS) today announced that it will release its Fourth Quarter 2020 and Year End operational results after market close on Wednesday March 31, 2021. StageZero’s Chairman and CEO, James R Howard-Tripp, will host a conference call and online presentation at 8:30 am ET on Thursday April 1, 2021 to review the operational results and discuss business developments for the period and to date.

Analyst and Investor Call

Event Date: Thursday April 1, 2021
Time: 8:30 AM ET
Webcast Link: https://www.webcaster4.com/Webcast/Page/2082/40528
Participant Numbers: Toll Free: 877-407-8031

International: 201-689-8031
Replay Number: Toll Free: 877-481-4010
International: 919-882-2331

Replay Passcode: 40528

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. www.stagezerolifesciences.com

Company Contacts:

James R. Howard-Tripp
Chairman & CEO

Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd

View source version on accesswire.com:
https://www.accesswire.com/638438/StageZero-Announces-2020-Year-End-Analyst-and-Investor-Call

Staff

Recent Posts

AsyncHealth launches Crowdfunding Campaign on StartEngine using Artificial Intelligence to Revolutionize Mental Health Care

AsyncHealth has a clinician-built platform that uses AI to streamline the delivery of mental health…

50 minutes ago

Lyra Growth Partners Inc. Announces Sale of Common Shares of BuildDirect.com Technologies Inc.

Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Lyra Growth Partners Inc. ("Lyra") announces…

5 hours ago

SCAN Named the Winner of the 2025 Hearst Health Prize

$100,000 Hearst Health Prize recognizes innovative initiatives using data science to make a health impact…

7 hours ago

Nanalysis Announces First Quarter 2025 Results

Delivers Another Quarter of Positive Adjusted EBITDA & Operating Cash Flow CALGARY, AB, May 28,…

7 hours ago

Veeva Announces Fiscal 2026 First Quarter Results

Total Revenues of $759.0M, up 17% Year Over YearSubscription Services Revenues of $634.8M, up 19%…

7 hours ago

Staffency, a TotalMed Company, Announces Merger with SimpliFi to Enhance Workforce Solutions

APPLETON, Wis., May 28, 2025 /PRNewswire/ -- Staffency, a premier workforce solutions provider and division…

7 hours ago